Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | ANPEP | P15144 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18462537 | 1.00 | PEPD (0.47) | PEPDMMP2ANPEPCYP3A4CYP1A2 | |
| SCHEMBL18589421 | 1.00 | PEPD (0.47) | PEPDMMP2ANPEPCYP3A4CYP1A2 | |
| SCHEMBL16357004 | 1.00 | PEPD (0.47) | PEPDMMP2ANPEPCYP3A4CYP1A2 | |
| SCHEMBL882756 | 1.00 | PEPD (0.47) | PEPDMMP2ANPEPCYP3A4CYP1A2 | |
| SCHEMBL14205631 | 1.00 | PEPD (0.47) | PEPDMMP2ANPEPCYP3A4CYP1A2 | |
| SCHEMBL24645309 | 1.00 | PEPD (0.47) | PEPDMMP2ANPEPCYP3A4CYP1A2 | |
| SCHEMBL4703753 | 0.90 | CHRM2 (0.42) | PEPDCYP3A4CYP1A2POLBCYP2C19 | |
| SCHEMBL27017249 | 0.90 | CHRM2 (0.42) | PEPDCYP3A4CYP1A2POLBCYP2C19 | |
| SCHEMBL20006799 | 0.88 | MMP2 (0.41) | PEPDMMP2ANPEPCYP3A4CYP1A2 | |
| SCHEMBL1412106 | 0.88 | CYP3A4 (0.53) | PEPDMMP2ANPEPCYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11865108-B2 | Nitrogen containing bicyclic compounds | WOCKHARDT LIMITED (IN) | 2024-01-09 | — | — | US | disclosed |
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230348462-A1 | IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2023-11-02 | — | — | US | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4045040-B1 | NITROGEN CONTAINING BICYCLIC COMPOUNDS | WOCKHARDT LTD (IN) | 2023-04-05 | — | — | EP | disclosed |
| US-20220378759-A1 | NITROGEN CONTAINING BICYCLIC COMPOUNDS | WOCKHARDT LIMITED (IN) | 2022-12-01 | — | — | US | disclosed |
| EP-4045040-A1 | NITROGEN CONTAINING BICYCLIC COMPOUNDS | Wockhardt Limited (IN) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021239863-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LIMITED (GB) | 2021-12-02 | — | — | WO | disclosed |
| US-9994614-B2 | N-methyl-D-aspartate receptor modulators and methods of making and using same | NAUREX, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| WO-2011059887-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059850-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110105520-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | PEPD 3712/4885MMP2 3653/4885ANPEP 1807/4885 |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | PEPD 71/4885MMP2 45/4885ANPEP 58/4885 |
| US-20230348462-A1 | IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | PEPD 4718/4885MMP2 4720/4885ANPEP 4478/4885 |
| US-20110105520-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | OPRD1, OPRK1, OPRM1 | PEPD 3579/4885MMP2 4837/4885ANPEP 4177/4885 |
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | NPFFR1, NPFFR2, NPBWR1 | PEPD 108/4885MMP2 2459/4885ANPEP 93/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | PEPD 194/4885MMP2 40/4885ANPEP 84/4885 |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | PEPD 254/4885MMP2 33/4885ANPEP 274/4885 |
| US-20220378759-A1 | NITROGEN CONTAINING BICYCLIC COMPOUNDS | NUCB2, NRDC, NCF1 | PEPD 555/4885MMP2 1559/4885ANPEP 305/4885 |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | PEPD 2/4885MMP2 295/4885ANPEP 53/4885 |
| US-11865108-B2 | Nitrogen containing bicyclic compounds | NUCB2, NRDC, NCF1 | PEPD 555/4885MMP2 1559/4885ANPEP 305/4885 |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP7 | PEPD 6/4885MMP2 45/4885ANPEP 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.